Euglycemic DKA (euDKA) is an underdiagnosed endocrine emergency and may not be treated appropriately treated due to lower than expected glucose levels. EuDKA has been increasing in prevalence due to the use of SGLT2-inhibitors. Glycemic or insulin outcomes for hospitalized patients with euDKA have been limited to case reports and series and have not been reported in a large cohort. Individual-level data were extracted from the Glytec Inpatient Database from 154 hospitals across the United States from (2017-2021) . All patients were on Glucommander IV, a computerized continuous insulin infusion (CII) algorithm, for at least 1 hour, to examine glycemic outcomes and insulinometrics. EuDKA was defined as patients with age ≥18 years with a BG < 250 mg/dl and who met the following criteria on admission: bicarbonate <18 mmol/L, pH <7.3, with ketones present in serum or urine. All patients had an ICD of Eor Eor A1c >6.5%. We identified 533 patients with euDKA (Table) . Time to HCO3 > 18 mEq/L was 14.1 hours. The incidence of hypoglycemia was low. Analysis of a nationwide cohort shows that euDKA can be safely and effectively treated with a computerized algorithm in the hospital, as patients achieved rapid time to target, resolution of DKA, and low mortality.
J.Messler: Employee; Glytec, LLC. P.Vellanki: n/a. R.Booth: Employee; Glytec, LLC.